À§¾ÏȯÀÚ 900¿¹ÀÇ ÀÓ»óºÐ¼® ¹× »ýÁ¸À²ÀÇ º¯È
Serial Clinical Analysis and Survival Rate of 900 Patients Treated for Malignant Gastric Tumor
´ëÇÑ¿Ü°úÇÐȸÁö 1993³â 45±Ç 6È£ p.792 ~ p.802
ÀÌÁ¾¼(Lee Jong-Seo) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶¿øÀÏ(Cho Won-Il) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶¿øÀÏ(Cho Won-Il) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À¯½ÂÁø(Yoo Seung-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±èÀÀ±¹(Kim Eung-Kook) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Àå¼®±Õ(Chang Suk-Kyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è½Â³²(Kim Seung-Nam) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¼Û¿µÅÃ(Song Young-Tack) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÌÀçÇÐ(Lee Jai-Hak) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÁÖ»ó¿ë(Choo Sang-Yong) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Abstract
Stomach cancer is the most common malignant tumor in Korea. This study includes 900 stomach cancer cases which were collected at the Department of Surgery, at. Mary, s Hospital. Catholic University Medical College over the period from 1980 to 1991.
The patients are divided into two groups:
1) Those treated during the period between 1980 and l986
2) Those treated during the period between 1987 and 1991
For the purpose of this article, we will call the first half period(1980~ 1986 r "first group" the second half period(1987 ~ 1991 r¡¯, second group ". We followed each patient and then analyzed each patient record using guidelines from the stomach cancer group of Korean surgical Society. The summarized results are provided as follows:
1) There were 885 adenocarcinomas(98.3%), 10 malignant lymphomas(1.1%), 5 leiomyosar comasm. 0.5% ) and 1 leiomyoblastoma(0.1% ).
2) There were 378 patients in the first group and 522 in the second group. The number of sec and group patients was 1.4 times as many as compared to the first group.
3) peak age incidence was 6th decade(31.1%) and male to female ratio was 1.8 : 1. The difference about age and sex between groups was insignificant. The number of patient under 35 years old was 87 cases(9.8%).
4) tumor locations were antrum(62.8% ), body(27.4% ), cardia(5.3% ) and whole stomach(3.7% ).
a. In the first group, tumor locations were antrum(67.6%), body(21.8%), cardia(5.1%) and whole stomach (5.3% ).
b. In the second group, tumor locations were antrum(59.8%), body(31.7%), cardia(6%) and whole stomach(2.5% ). The tumor location of the second group is in the higher portion of stomach than first group.
5) Operation procedures performed were subtotal gastrectomy(69.1%), total gastrectomy(18.7%), bypass gastrojejunostomy(4.6%), exploratory surgery(6.3%) and proximal gastrectomy(0.8%) and so gastic resection are was 88.6% in total.
a. In the first group, operation procedures performed wore subtotal gastrectomy(71.2%), total gastrectomy(15.9%), exploratory surgery(7.9%) and bypass gastrojejunostomy(4%).
b. In the second group, operation procedures performed were subtotal gastrectomy(67.6%), total gastrectomy(20.7%), exploratory surgery(5.2%) and bypass gastrojejunostomy(5%).
Total gastrectomy of the second group has increased compared to first group; while exploratory surgery has decreased.
6) Regional lymph node metastasis was seen in 60.8% of all cases. Rate of Regional lymph node metastasis according to tumor depth were as follows; 16% in T1, 48.4% in T2, 77.3% in T3 and 92.5% in T4.
7) There were 162 cases of early gastric cancer(18%): 14% in the first group, 20% in the second group. The rate of EGC has significantly increased every year(P<0.05).
8) Overall 5-years-cumlative survival rate was 55.8%.
9) Overall 5-year-cumulative survival rate according to stage were as follows: 98.6% in stage Ia, 89.6% in Ib, 67% in II, 58.4% in IIIa. 29.4% in IIIb and 14% in stage IV.
10) Overall 5-year-cumulative survival rates according to depth were as follow: 93.9% in T1, 85% in T2 48.8% in T3 and 12.4% in T4.
11) Hospital dath rate was 1.5%.
Å°¿öµå
Segmental dilatation, Colon, Neonate
KMID :
0371319930450060792
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Overall 5-year-cumulative survival rate according to stage were as follows: 98.6% in stage Ia, 89.6% in Ib, 67% in II, 58.4% in IIIa. 29.4% in IIIb and 14% in stage IV.